317 related articles for article (PubMed ID: 17625515)
1. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.
Rudberg I; Mohebi B; Hermann M; Refsum H; Molden E
Clin Pharmacol Ther; 2008 Feb; 83(2):322-7. PubMed ID: 17625515
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
3. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.
Ohlsson Rosenborg S; Mwinyi J; Andersson M; Baldwin RM; Pedersen RS; Sim SC; Bertilsson L; Ingelman-Sundberg M; Eliasson E
Eur J Clin Pharmacol; 2008 Dec; 64(12):1175-9. PubMed ID: 18654768
[TBL] [Abstract][Full Text] [Related]
5. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).
Rudberg I; Hendset M; Uthus LH; Molden E; Refsum H
Ther Drug Monit; 2006 Feb; 28(1):102-5. PubMed ID: 16418702
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients.
Rudberg I; Hermann M; Refsum H; Molden E
Eur J Clin Pharmacol; 2008 Dec; 64(12):1181-8. PubMed ID: 18677622
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro.
Rudberg I; Reubsaet JL; Hermann M; Refsum H; Molden E
Drug Metab Dispos; 2009 Dec; 37(12):2340-8. PubMed ID: 19773541
[TBL] [Abstract][Full Text] [Related]
10. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
Jin Y; Pollock BG; Frank E; Cassano GB; Rucci P; Müller DJ; Kennedy JL; Forgione RN; Kirshner M; Kepple G; Fagiolini A; Kupfer DJ; Bies RR
J Clin Pharmacol; 2010 Jan; 50(1):62-72. PubMed ID: 19841156
[TBL] [Abstract][Full Text] [Related]
11. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker.
Noehr-Jensen L; Zwisler ST; Larsen F; Sindrup SH; Damkier P; Nielsen F; Brosen K
Eur J Clin Pharmacol; 2009 Sep; 65(9):887-94. PubMed ID: 19404631
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
Jan MW; ZumBrunnen TL; Kazmi YR; VanDenBerg CM; Desai HD; Weidler DJ; Flockhart DA
Drug Metabol Drug Interact; 2002; 19(1):1-11. PubMed ID: 12222750
[TBL] [Abstract][Full Text] [Related]
17. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19.
Holmgren P; Carlsson B; Zackrisson AL; Lindblom B; Dahl ML; Scordo MG; Druid H; Ahlner J
J Anal Toxicol; 2004 Mar; 28(2):94-104. PubMed ID: 15068562
[TBL] [Abstract][Full Text] [Related]
18. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles.
Suzuki Y; Shioiri T; Muratake T; Kawashima Y; Sato S; Hagiwara M; Inoue Y; Shimoda K; Someya T
Eur J Clin Pharmacol; 2003 Apr; 58(12):829-33. PubMed ID: 12698310
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
20. A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Bråten LS; Haslemo T; Jukic MM; Ivanov M; Ingelman-Sundberg M; Molden E; Kringen MK
Clin Pharmacol Ther; 2021 Sep; 110(3):786-793. PubMed ID: 33759177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
